| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
NeuroPace (NASDAQ:NPCE) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 3 | 2 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 1 | 0 | 0 |
| 3M Ago | 0 | 2 | 1 | 0 | 0 |
Analysts have recently evaluated NeuroPace and provided 12-month price targets. The average target is $11.83, accompanied by a high estimate of $22.00 and a low estimate of $8.00. This upward trend is apparent, with the current average reflecting a 47.88% increase from the previous average price target of $8.00.
A comprehensive examination of how financial experts perceive NeuroPace is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Mike Kratky | Leerink Partners | Announces | Outperform | $22.00 | - |
| Frank Takkinen | Lake Street | Maintains | Buy | $12.00 | $12.00 |
| Drew Ranieri | Morgan Stanley | Raises | Equal-Weight | $9.00 | $8.00 |
| Drew Ranieri | Morgan Stanley | Raises | Equal-Weight | $8.00 | $6.00 |
| Ross Osborn | Cantor Fitzgerald | Announces | Overweight | $11.00 | - |
| Robbie Marcus | JP Morgan | Raises | Overweight | $9.00 | $6.00 |
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of NeuroPace's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on NeuroPace analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, NeuroPace showcased positive performance, achieving a revenue growth rate of 47.23% as of 30 September, 2023. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: NeuroPace's net margin excels beyond industry benchmarks, reaching -44.18%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): NeuroPace's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -38.61%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): NeuroPace's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -7.2%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: NeuroPace's debt-to-equity ratio stands notably higher than the industry average, reaching 4.38. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: NPCE
